GlassScriptPhysician profile
Lori A Long
NPI 1477685931
$2,885.89
in general payments reported to CMS, 2019-2025
23 companies · $607 in 2025
The $607 reported for 2025 was more than what 82% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $195 · 2020: $205 · 2021: $571 · 2022: $275 · 2023: $761 · 2024: $272 · 2025: $607.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,565 · Long Term Medical Supply Or Device Loan: $75.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,564.69 |
| Long Term Medical Supply Or Device Loan | $75.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $313.43 | 2020-2023 | Cequa |
| Glaukos Corporation | $286.64 | 2019-2025 | Radius Xr |
| Bausch & Lomb Americas INC. | $247.46 | 2023-2025 | Miebo, Xiidra |
| Ocular Therapeutix, INC. | $243.46 | 2023-2025 | Dextenza |
| Rxsight INC | $237.52 | 2022 | |
| Alcon Vision LLC | $186.19 | 2019-2025 | Tryptyr |
| Sight Sciences, INC. | $158.39 | 2023-2025 | Omni Surgical System, Tearcare System |
| Tarsus Pharmaceuticals, INC. | $157.34 | 2024-2025 | Xdemvy |
| Harrow Eye, LLC | $125.00 | 2025 | Vevye |
| Johnson & Johnson Surgical Vision, INC. | $123.39 | 2021 | |
| Aerie Pharmaceuticals, INC. | $122.67 | 2019-2021 | |
| Apellis Pharmaceuticals, INC. | $106.49 | 2023 | Syfovre |
| Horizon Therapeutics Plc | $99.42 | 2023 | Tepezza |
| Lombart Brothers, INC. | $92.72 | 2020 | |
| Genentech USA, INC. | $90.23 | 2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $89.94 | 2021-2025 | Oxervate |
| Coopervision INC. | $82.18 | 2024 | Misight Contact Lens |
| Abbvie INC. | $31.66 | 2024 | |
| Biotissue Holdings INC. | $22.76 | 2025 | |
| Notal Vision, INC. | $22.22 | 2024 | Foresee Home |
| Johnson & Johnson Vision Care, INC. | $19.30 | 2019 | |
| Allergan, INC. | $15.53 | 2021 | |
| Novartis Pharmaceuticals Corporation | $11.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori Long listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.